BCAX Bicara Therapeutics Inc.
Price Chart
Executive Summary
Bicara Therapeutics reported Q1 2026 net loss of $56.2M ($-0.93/share), wider than the $-0.68 loss in Q1 2025, driven by increased R&D spend on the FORTIFI-HN01 pivotal trial. The company has $539.8M in cash, extended runway into H1 2029, and announced key clinical and executive milestones including a planned Q3 2026 randomized dosing study and ASCO 2026 data presentation. This is a pre-revenue clinical-stage biotech — the widening loss is expected and not a surprise; the stock will move on clinical catalysts, not quarterly financials.
Actionable Insight
The stock will trade on ASCO 2026 data (May 29-June 2) and the Q3 2026 dosing study initiation, not on the quarterly loss. Monitor for interim analysis readout from FORTIFI-HN01 expected mid-2027. The $539.8M cash position removes near-term financing risk.
Key Facts
- Net loss of $56.2M for Q1 2026 vs $36.8M in Q1 2025
- Cash, cash equivalents and marketable securities of $539.8M as of March 31, 2026
- Cash runway extended into first half of 2029
- Plan to initiate randomized study of loading + Q3W maintenance dosing in Q3 2026
- Long-term follow-up data from Phase 1b to be presented at ASCO 2026 (May 29-June 2)
- Bill Schelman promoted to CMO; Chris Sarchi appointed as Chief Commercial Officer
- R&D expenses $47.5M in Q1 2026 vs $34.3M in Q1 2025
- Net loss per share $-0.93 vs $-0.68 in prior year period
Financial Impact
Net loss widened by $19.4M YoY to $56.2M; cash position $539.8M provides runway into H1 2029
Risk Factors
- Clinical trial failure or disappointing ASCO data
- Dilution risk if additional financing needed before potential approval
- Regulatory delays in dosing study or accelerated approval pathway
Market Snapshot
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001628280-26-033135 |
| Document: bcax-20260511.htm | 0001628280-26-033135 |
| Document: 0001628280-26-033135-index-headers.html | 0001628280-26-033135 |
| Document: 0001628280-26-033135-index.html | 0001628280-26-033135 |
| Document: 0001628280-26-033135.txt | 0001628280-26-033135 |
| 8-K Data (Synthetic) | 0001628280-26-033135 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
May 11, 2026
9d ago
|
8-K
| $22.92 $19.29 | ▼ −15.84% | ▼ −15.75% | $20.43 (−10.86%) |
|
May 4, 2026
16d ago
|
Press Release
| $22.72 $22.92 | ▲ +0.88% | ▼ −2.06% | $20.43 (−10.08%) |
|
Apr 27, 2026
23d ago
|
DEFA14A
| $22.48 $22.72 | ▲ +1.09% | ▲ +0.69% | $20.43 (−9.10%) |
|
Apr 20, 2026
4w ago
|
Insider Cluster
| — | awaiting T+5 | — | — |
|
Apr 15, 2026
5w ago
|
Insider Cluster
| $23.72 $23.63 | ▼ −0.38% | ▼ −2.02% | $20.43 (−13.87%) |
|
Apr 15, 2026
5w ago
|
Insider Cluster
| $23.72 $23.63 | ▲ +0.38% | ▲ +2.02% | $20.43 (+13.87%) |
|
Apr 3, 2026
6w ago
|
Press Release
| $20.85 $22.14 | ▲ +6.19% | ▲ +2.05% | $20.43 (−2.01%) |
|
Mar 23, 2026
8w ago
|
Press Release
| $18.39 $19.04 | ▲ +3.53% | ▲ +7.10% | $20.43 (+11.09%) |
|
Mar 16, 2026
9w ago
|
Insider Cluster
| $19.40 $18.39 | ▼ −5.21% | ▼ −3.16% | $20.43 (+5.31%) |
|
Mar 16, 2026
9w ago
|
Insider Cluster
| $19.40 $18.39 | ▼ −5.21% | ▼ −3.16% | $20.43 (+5.31%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access